Sym001 Co-development and Commercialization Agreement with Biovitrum
In January 2006, Symphogen entered into a co-development and commercialization agreement with Biovitrum for its lead product Sym001 (Anti-RhD) for treatment of the blood disorders Idiopathic Thrombocytopenic Purpura (ITP) and prevention of Hemolytic Disease in Newborns (HDN). Under the terms of the agreement, Symphogen received an initial technology access fee from Biovitrum, and may receive milestone payments based on the progress of the Sym001 program. If successfully developed, Sym001 would be marketed by Symphogen in North America, Central America and South America, and by Biovitrum in Europe, Russia and the Middle East. The companies intend to seek partners for commercialization in the rest of the world.

Sym002 Development Grant with NIAID/NIH
In July 2006, Symphogen was awarded a $4.6 million grant by the U.S. National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH) for the full preclinical development of Sym002, Symphogen’s anti-vaccinia product for the adverse reactions associated with smallpox vaccination. The grant should allow Symphogen to complete the pre-clinical development of Sym002, the conclusion of which could enable the Company to submit an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) for initial safety studies.

Sym006 Development and License Agreement with Meiji Seika Kaisha
In December 2006, Symphogen entered into a development and license agreement with Meiji Seika Kaisha (Tokyo, Japan) for Sym006, a recombinant polyclonal antibody product candidate against an undisclosed bacterial target. Under the terms of the agreement, Symphogen received an upfront technology access fee. Meiji will fund all the discovery and development activities, and Symphogen is entitled to receive milestones upon successful product development achievements. If successfully commercialized, Symphogen would receive royalties on net sales of product. Importantly, in the collaboration, Symphogen retained an option to become a 50/50 co-development partner in the U.S. and EU territories after completion of Phase 2 clinical studies.

Sym008 strategic collaboration with Genentech
In June 2008 Symphogen entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets.
In the collaboration, Symphogen would apply its proprietary Symplex™ antibody discovery technology platform to identify novel infectious disease drug candidates.   Furthermore, Genentech Would gain access to Symphogen’s Sympress™ technology to produce recombinant polyclonal antibodies.
Under the terms of the agreement, Genentech would make an undisclosed upfront payment to Symphogen, as well as an equity investment in Symphogen. In addition, Symphogen was eligible to receive milestone payments upon the success of certain research and development milestones, as well as royalties on any products developed and commercialized by Genentech as a result of this collaboration. The total value of the agreement had the potential to exceed $ 330 million and Genentech would obtain an exclusive worldwide license to candidates developed through this agreement, and would fund associated research and development costs.

 

Sym001
Sym006